Novartis has said it will spend up to $16bn on GlaxoSmithKline's cancer drug assets, as part of a flurry of other multi-billion dollar pharmaceuticals deals that also involve industry stablemate Eli Lilly.
Novartis will buy Glaxo's oncology business for as much as $16bn and the two companies will form a consumer health venture.
Separately, Novartis will sell Glaxo its vaccines business, excluding flu products, for $7.1 bn plus royalties.
您已閱讀13%（439字），剩餘87%（3019字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。